Payment overview · 2025
General Payments
$729.02
31 reported records · 11 companies
Healthcare provider profile · identity verified
Amina Baloch, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · OAKBROOK TERRACE, IL · NPI 1336698901
Verified facts
What the public records show
CMS Open Payments records show Amina Baloch, APN received $729.02 in general payments during 2025 across 31 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Gemtesa.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $321.99 | 44.2% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $123.09 | 16.9% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $56.05 | 7.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.11 | 7.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.52 | 6.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.39 | 4.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.91 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.16 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.24 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.10 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.46 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.02 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $321.99 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $123.09 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $77.91 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.11 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 192 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
192 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 33 |
| Memantine Hcl | Memantine Hcl | 243 | 13 |
| Furosemide | Furosemide | 227 | 24 |
| Simvastatin | Simvastatin | 203 | 15 |
| Warfarin Sodium | Warfarin Sodium | 199 | suppressed |
| Gemtesa | Vibegron | 192 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 12 |
| Lisinopril | Lisinopril | 149 | 17 |
| Eliquis | Apixaban | 140 | 13 |
| Gabapentin | Gabapentin | 124 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 23 |
| Divalproex Sodium | Divalproex Sodium | 114 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 114 | suppressed |
| Potassium Chloride | Potassium Chloride | 111 | 16 |
| Mirtazapine | Mirtazapine | 108 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | suppressed |
| Metformin Hcl | Metformin Hcl | 105 | 16 |
| Carvedilol | Carvedilol | 102 | suppressed |
| Levetiracetam | Levetiracetam | 97 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 90 | suppressed |
| Xarelto | Rivaroxaban | 89 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 88 | 20 |
| Glipizide | Glipizide | 85 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 78 | suppressed |
| Famotidine | Famotidine | 77 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 77 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | suppressed |
| Glipizide Er | Glipizide | 50 | suppressed |
| Tradjenta | Linagliptin | 50 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Omeprazole | Omeprazole | 46 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 14 |
| Lactulose | Lactulose | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Mometasone Furoate | Mometasone Furoate | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Calcium Acetate | Calcium Acetate | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Losartan Potassium | Losartan Potassium | 29 | suppressed |
| Nystatin | Nystatin | 29 | 19 |
| Cephalexin | Cephalexin | 28 | 25 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 11 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Prednisone | Prednisone | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 14 |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 12 |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.02 · 31 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AUSTEDO XR, CAPLYTA, EPIDIOLEX, GEMTESA, INGREZZA, REXULTI, The Cologuard Plus Collection Kit, UZEDY, VOQUEZNA, VRAYLAR, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Sumitomo Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error